According to FutureWise analysis the market for polycythemia vera is expected to register a CAGR of 7.4% from 2023-2031.
The condition polycythemia vera is characterized by an overproduction of blood cells in the bone marrow (myeloproliferative). Most cases involve an increase in red blood cell production, but also the production of platelets and white blood cells. Red blood cells are excessively produced in the marrow. This results in abnormally high levels of red blood cells in the blood. Hyperviscosity is a condition where blood volume increases and thickens. Thinner blood might not be able to flow properly through smaller blood vessels. Polycythemia vera can cause a wide range of symptoms, including fatigue, headaches, dizziness, weakness, itchy skin, and enlarged spleens (splenomegaly). Blood clots may also occur, which could prevent blood from flowing to vital organs like the heart, lungs, or kidneys. There are no symptoms or signs in the initial stages. If there are too many RBCs or platelets in the blood, symptoms may start to develop. Although symptoms may not be apparent due to an increase in cell count, they can indicate a greater risk of clot formation. The symptoms of PV include headaches, dizziness and fatigue, blurred vision, blind spots, shortness of no breath, itchy skin (Splenomegaly), blood clots, heavy bleeding, and other symptoms. The average age at which polycythemia vera is diagnosed is 60-65 years. It is rare in those under 40. PV is more common in men than it is in women. People with PV don't have any family history. The cause of PV is a mutation in the JAK2 Kinase( also known as JAK2, this is a non-receptor tyrosine kinase). PV is usually caused by somatic genetic changes, and not in the egg or sperm cells that pass genetic information on to offspring. Sometimes, enlarged spleens can cause pain and problems for patients. For that reason, surgery is performed to remove the spleen. There is no single treatment that has proven to be effective for everyone. The outcome of PV depends on the patient's willingness to receive treatment. The treatment helps to reduce the chance of serious complications such as myelofibrosis (myeloma), heart attack, ischemic strokes, pulmonary embolisms, portal hypertension, acute meeloid leukemia, and ischemic stroke. Although complications of PV can occur even with treatment, the risk is lower. Treatment of PV aims to reduce symptoms and the chance of complications, including stroke and heart attack. PV treatments decrease the number of red blood cells in the blood and increase hemoglobin (an iron-rich protein). This brings the blood thickness closer to normal.
Myelosuppressive drugs are used to suppress the formation and growth of blood cells in the bone marrow. Hydroxyurea, a chemotherapy drug also known as Busulfan, is the most common. In the past, other drugs such as radioactive phosphorous and chlorambucil were used. These drugs have been linked to an increased risk of developing Leukemia, particularly in those who require long-term treatment.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Polycythemia Vera Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Polycythemia Vera Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.